Advancing human health risk assessment: Integrating recent advisory committee recommendations

Critical Reviews in Toxicology

Volumn 43, Issue 6, 2013, Pages 467-492

  Dourson, Michael ^a   Becker, Richard A ^b   Haber, Lynne T ^a   Pottenger, Lynn H ^c   Bredfeldt, Tiffany ^d   Fenner Crisp, Penelope A ^e  

^a Toxicology Excellence for Risk Assessment   (United States)

^b American Chemistry Council   (United States)

^c DOW CHEMICAL COMPANY   (United States)

^d Texas Commission on Environmental Quality   (United States)

^e Independent Researcher   (United States)

Author keywords

Biomonitoring equivalents; Chemical specific adjustment factor (CSAF); Combined exposures; Critical effect; Dose dependent transitions; Harmonized dose response assessment; Mode of action (MOA); Problem formulation; Safe dose

Indexed keywords

CHLORPYRIFOS; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; FORMALDEHYDE; PESTICIDE; PHTHALIC ACID DERIVATIVE;

ADVISORY COMMITTEE; BIOLOGICAL MONITORING; BIOPROCESS; CELL PROLIFERATION; CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; CHEMICAL SPECIFIC ADJUSTMENT FACTOR; CHOLINESTERASE INHIBITION; CLINICAL PROTOCOL; CONCEPTUAL FRAMEWORK; CONSENSUS; DNA REPAIR; DOSE RESPONSE; DRUG EXPOSURE; DRUG INFORMATION; DRUG SAFETY; GENOTOXICITY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH HAZARD; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KNOWLEDGE; NONHUMAN; PHARMACODYNAMICS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; TOXICITY TESTING; TOXICODYNAMICS; TOXICOKINETICS; UNCERTAINTY; WORLD HEALTH ORGANIZATION; XENOBIOTIC METABOLISM;

ADVISORY COMMITTEES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL MONITORING; HUMANS; NEOPLASMS; PUBLIC HEALTH; RISK ASSESSMENT; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY;

EID: 84880310513     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2013.807223     Document Type: Review

References (202)

1. ACGIH (American Conference of Governmental and Industrial Hygienists). (2011). TLVs and BEIs based on the documentation of the "Threshold limit values for chemical substances and physical agents and biological exposure indices". p. 78.
2. Aldridge BB, Burke JM, Lauffenburger DA, Sorger PK. (2006). Physicochemical modeling of cell signaling pathways. Nat Cell Biol, 8, 1195-203.
3. Allen B, Maier A, Willis A, Haber LT. (2013). Use of early effect biomarker data to enhance dose-response models of lung tumors in rats exposed to titanium dioxide. Submitted.
4. Alon U. (2007). Network motifs: theory and experimental approaches. Nat Rev Genet, 8, 450-61.
5. ARA (Alliance for Risk Assessment). (2013). Beyond science and decisions: from problem formulation to dose response. Available from: http://www. allianceforrisk.org/ARA-Dose-Response.htm [last accessed 10 March 2013].
6. Andersen ME, Krewski D. (2009). Toxicity testing in the 21st century: bringing the vision to life. Toxicol Sci, 107, 324-30.
7. Angerer J, Aylward LL, Hays SM, et al. (2011). Human biomonitoring assessment values: approaches and data requirements. Int J Hyg Environ Health, 241, 348-60.
8. ATSDR. (2001a). Guidance manual for the assessment of joint toxic action of chemical mixtures. Atlanta, GA: Agency for Toxic Substances and Disease Registry, Public Health Service, U.S. Department of Health and Human Services.
9. ATSDR. (2001b). Guidance manual for the preparation of an interaction profile. Atlanta, GA: Agency for Toxic Substances and Disease Registry, Public Health Service, U.S. Department of Health and Human Services.
10. Aylward LL, Kirman CR, Schoeny R, et al. (2013). Evaluation of biomonitoring data from the CDC National exposure report in a risk assessment context: perspectives across chemicals. Environ Health Perspect, 121, 287-94. doi: 10.1289/ehp.1205740.
11. Bachmann J. (2007). Will the circle be unbroken: a history of the U.S. national ambient air quality standards. J Air Waste Manage Assoc, 57, 652-97.
12. Baird JS, Cohen JT, Graham JD, et al. (1996). Noncancer risk assessment: probabilistic characterization of population threshold doses. J Hum Ecol Risk Assess, 2, 79-102.
13. Balakrishnan N, ed. (1991). Handbook of the logistic distribution. New York, NY: CRC Press.
14. Ball G. (2011). Personal communication with M. Dourson, Toxicology Excellence for Risk Assessment (TERA), Cincinnati, Ohio, August 23.
15. Barnes DG, Dourson ML. (1988). Reference dose (RfD): description and use in health risk assessments. Regul Toxicol Pharmacol, 8, 471-86.
16. Becker RA, Hays SM, Robison S, Aylward, LL. (2012). Development of screening tools for the interpretation of chemical biomonitoring data. J Toxicol Article ID 941082, 10 pages. Available from: http://www.hindawi.com/journals/ jt/2012/941082/[last accessed 10 March 2013].
17. Birnbaum L, Damstra T, Hart J, et al. (2001). Integrated risk assessment: a report prepared for the WHO/UNEP/ILO International Programme on Chemical Safety. WHO/IPCS/IRA/01/12.
18. Boekelheide K, Andersen ME. (2010). A mechanistic redefinition of adverse effects - a key step in the toxicity testing paradigm shift. Altex, 27, 243-52.
19. Bogen KT. (2008). An adjustment factor for mode-of-action uncertainty with dual-mode carcinogens: the case of naphthalene-induced nasal tumors in rats. Risk Anal, 28, 1033-51.
20. Bois FY, Jamei M, Clewell HJ. (2010). PBPK modeling of interindividual variability in the pharmacokinetics of environmental chemicals. Toxicology, 278, 256-67.
21. Boobis AR, Daston G, Preston J, Olin S. (2009). Application of key events analysis to chemical carcinogens and noncarcinogens. Crit Rev Food Sci Nutr, 49, 690-707.
22. Borgert CJ, Sargent EV, Casella G, et al. (2012). The human relevant potency threshold: reducing uncertainty by human calibration of cumulative risk assessments. Regul Toxicol Pharmacol, 62, 313-28.
23. Bryce SM, Avlasevich SL, Bemis JC, et al. (2010). Miniaturized flow cytometric in vitro micronucleus assay represents an efficient tool for comprehensively characterizing genotoxicity dose-response relationships. Mutat Res, 703, 191-9.
24. Bus JS, Becker RA. (2009). Toxicity testing in the 21st century: a view from the chemical industry. Toxicol Sci, 112, 297-302.
25. Carmichael N, Bausen M, Boobis AR, et al. (2011). Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview. Crit Rev Toxicol, 41, 175-86.
26. Chiu WA, Guyton KZ, Hogan K, Jinot J. (2012). Approaches to human health risk assessment based on the signal-to-noise crossover dose. Correspondence. Environ Health Perspect, 120, a264.
27. Clegg DJ. (1978). Toxicology basis of the ADI - present and future considerations. In: Frehse H, Geissbuhler H, eds. Pesticide reviews. Oxford, England: Pergamon Press, 74-7.
28. Cohen SM, Arnold LL. (2011). Chemical carcinogenesis. Toxicol Sci, 120, S76-92.
29. Committee on Biological Effects of Ionizing Radiation Committee (BEIR). (2006). Health risks from exposure to low levels of ionizing radiation: BEIR VII Phase 2. Nuclear and Radiation Studies Board, Division on Earth and Life Studies, National Research Council of the National Academies. Washington, DC: The National Academies Press.
30. Conolly RB, Kimbell JS, Janszen D, et al. (2003). Biologically motivated computational modeling of formaldehyde carcinogenicity in the F344 rat. Toxicol Sci, 75, 432-47.
31. Conolly RB, Lutz WK. (2004). Nonmonotonic dose-response relationships: mechanistic basis, kinetic modeling, and implications for risk assessment. Toxicol Sci, 77, 151-7.
32. Crump KS, Clewell III HJ, Andersen ME. (1997). Cancer and noncancer risk assessments should be harmonized. Human Ecol Risk Assess, 3, 495-9.
33. Crump KS, Clewell III HJ, Andersen ME. (1998). Cancer and non-cancer risk assessments should be harmonized. Comment Toxicol, 6, 277-82.
34. Dankovic D, Kuempel E, Wheeler M. (2007). An approach to risk assessment for TiO2. Inhal Toxicol, 19, 205-12.
35. Daston G, Faustman E, Ginsberg G, et al. (2004). A framework for assessing risks to children from exposure to environmental agents. Environ Health Persp, 112, 238-56.
36. DHHS (Department of Health and Human Services). (1991). Common Rule. National Institutes of Health, Office for Protection from Research Risks Title 45 Code of Federal Regulations Part 46. Protection of Human Subjects.
37. Doak SH, Jenkins GJ, Johnson GE, et al. (2007). Mechanistic influences for mutation induction curves after exposure to DNA-reactive carcinogens. Cancer Res, 67, 3904-11.
38. Dourson ML, Charnley G, Scheuplein R. (2002). Differential sensitivity of children and adults to chemical toxicity: II. Risk and regulation. Regul Toxicol Pharmacol, 35, 448-67. Available from: http://www.tera.org/Publications/ Dourson%202002.pdf [last accessed 10 March 2013].
39. Dourson ML, DeRosa CT. (1991). The use of uncertainty factors in establishing safe levels of exposure. In: Krewski D, Franklin C, eds. Statistics in toxicology. New York, NY: Gordon and Breach Science Publishers, 613-27.
40. Dourson ML, Felter SP, Robinson D. (1996). Evolution of science-based uncertainty factors in noncancer risk assessment. Regul Toxicol Pharmacol, 24, 108-20.
41. Dourson, ML, Haber, LT. (2010). Linear low-dose extrapolations. In: Hsu CH, Stedeford T, eds. Cancer risk assessment, chemical carcinogenesis, hazard evaluation, and risk quantification. Hoboken, NJ: John Wiley & Sons, Inc., pp. 615-35.
42. Dourson ML, Hertzberg R, Allen B, et al. (2008). Evidence-based dose response assessment for thyroid tumorigenesis from acrylamide. Regul Toxicol Pharmacol, 52, 264-89.
43. Dourson ML, Knauf LA, Swartout JC. (1992). On reference dose (RfD) and its underlying toxicity data base. Toxicol Ind Health, 8, 171-89.
44. Dourson ML, Maier A, Meek B, et al. (1998). Re-evaluation of toxicokinetics for data-derived uncertainty factors. Biol Trace Element Res, 66, 453-63. Available from: http://www.tera.org/Publications/Boron1998.pdf [last accessed 10 March 2013].
45. Dourson ML, Stara JF. (1983). Regulatory history and experimental support of uncertainty (safety) factors. Regul Toxicol Pharmacol, 3, 224-38.
46. EFSA (European Food Safety Authority). (2012). Statement on the applicability of the Margin of Exposure approach for the safety assessment of impurities which are both genotoxic and carcinogenic in substances added to food/feed. EFSA J, 10, 2578.
47. Fenner-Crisp P. (2001). The FQPA 10x safety factor - how much is science? how much is sociology? HERA, 7, 107-16.
48. Foster WG, Agzarian J. (2007). Reporting results of biomonitoring studies. Anal Bioanal Chem, 387, 137-40.
49. Ginsberg G, Hattis D, Sonawane B, et al. (2002). Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci, 66, 185-200.
50. Gocke E, Mu?ller L. (2009). In vivo studies in the mouse to define a threshold for the genotoxicity of EMS and ENU. Mutat Res, 678, 95-100.
51. Gollapudi BB, Johnson GE, Hernandez LG, et al. (2013). Quantitative approaches for assessing dose-response relationships in genetic toxicology studies. Environ Molec Mutagenesis, 54, 8-18.
52. Hack CE Haber LT, Maier A, et al. (2010). A Bayesian network model for biomarker-based dose response. Risk Anal, 30, 1037-51.
53. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell, 100, 57-70.
54. Hard GC, Rodgers IS, Baetcke KP, et al. (1993). Hazard evaluation of chemicals that cause accumulation of alpha 2u-globulin, hyaline droplet nephropathy, and tubule neoplasia in the kidneys of male rats. Environ Health Perspect, 99, 313-49.
55. Harrison M. (2008). Applying bioethical principles to human biomonitoring. Environ Health, 7, S8.
56. Hattis D. (1990). Pharmacokinetic principles for dose rate extrapolation of carcinogenic risk from genetically active agents. Risk Anal, 10, 303-16.
57. Hattis D, Banati P, Goble R, Burmaster DE. (1999). Human interindividual variability in parameters related to health risks. Risk Anal, 19, 711-26.
58. Hays SM, Aylward LL. (2009). Using biomonitoring equivalents to interpret human biomonitoring data in a public health risk context. J Appl Toxicol, 29, 275-88.
59. Hays SM, Aylward LL, LaKind JS, et al. (2008). Guidelines for the derivation of biomonitoring equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul Toxicol Pharmacol, 51, S4-15.
60. Hays SM, Becker RA, Leung HW, et al. (2007). Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. Regul Toxicol Pharmacol, 47, 96-109.
61. Hinderliter PM, Price PS, Bartels MJ, et al. (2011). Development of a source-to-outcome model for dietary exposures to insecticide residues: an example using chlorpyrifos. Regul Toxicol Pharmacol, 61, 82-92.
62. IPCS (International Programme on Chemical Safety). (1994). Environmental Health Criteria 170: assessing human health risks of chemicals: derivation of guidance values for health-based exposure limits. Geneva, Switzerland.
63. IPCS (International Programme on Chemical Safety). (2005). Chemicalspecific adjustment factors for interspecies differences and human variability: guidance document for use of data in dose/concentrationresponse assessment. Geneva, Switzerland. Available from: www.who.int/ipcs/methods/ harmonization/areas/uncertainty/en/index. html [last accessed 10 March 2013].
64. IPCS (International Programme on Chemical Safety). (2006). IPCS framework for analysing the relevance of a cancer mode of action for humans and case studies. Geneva, Switzerland. Available from: http://www.who.int/ipcs/methods/ harmonization/areas/cancer-mode.pdf [last accessed 10 March 2013].
65. IPCS (International Programme on Chemical Safety). (2010). Characterization and application of physiologically-based pharmacokinetic models in risk assessment. Available from: http://www.who.int/ipcs/methods/ harmonization/areas/pbpk-models.pdf [last accessed 10 March 2013].
66. Jarabek AM. (1994). Inhalation RfC methodology: dosimetric adjustments and dose-response estimation of noncancer toxicity in the upper respiratory tract. Inhal Toxicol, 6, 301-25.
67. Jarabek AM. (1995a). Interspecies extrapolation based on mechanistic determinants of chemical disposition. J Hum Ecol Risk Assess, 15, 641-52.
68. Jarabek AM. (1995b). The application of dosimetry models to identify key processes and parameters for default dose-response assessment approaches. Toxicol Lett, 79, 171-84.
69. Jarabek AM, Menach MG, Overton JH, et al. (1989). Inhalation reference dose (RfDi): an application of interspecies dosimetry modeling for risk assessment of insoluble particles. Health Phys, 57, 177-83.
70. Julien E, Boobis AR, Olin SS; The ILSI Research Foundation Threshold Working Group. (2009). The key events dose-response framework: a cross-disciplinary mode-of-action based approach to examining dose-response and thresholds. Crit Rev Food Sci Nutr, 49, 682-9.
71. Kalberlah F, Schneider K. (1998). Quantification of extrapolation factors. Final report of the research project No. 116 06 113. Germany. Federal Environmental Agency.
72. Keller DA, Juberg DR, Catlin N, et al. (2012). Identification and characterization of adverse effects in 21st century toxicology. Toxicol Sci, 126, 291-7.
73. Kirman CR, Albertini RA, Gargas ML. (2010). 1,3-Butadiene: III. Assessing carcinogenic modes of action. Crit Rev Toxicol, 40, 74-92.
74. Klassen C. (2008). Casarett & Doull's toxicology: the basic science of poisons, 7th ed. New York, NY: Mcgraw-hill medical Publishing Division. p. 23.
75. Kroes R, Munro I, Poulsen E. (1993). Workshop on the scientific evaluation of the safety factor for the acceptable daily intake (ADI): editorial summary. Food Add Contam, 10, 269-73.
76. LaKind JS, Aylward LL, Brunk C, et al. (2008a). Guidelines for the communication of biomonitoring equivalents: report from the biomonitoring equivalents expert workshop. Regul Toxicol Pharmacol, 51, 516-26.
77. LaKind JS, Baraj L, Tran N, Aylward LL. (2008b). Environmental chemicals in people: challenges in interpreting biomonitoring information. J Environ Health, 70, 61-4.
78. LaKind JS, Goodman M, Naiman DQ. (2012). Use of NHANES data to link chemical exposures to chronic diseases: a cautionary tale. PLoS ONE, 7, e51086. doi:10.1371/journal.pone.0051086
79. Lau C, Andersen ME, Crawford-Brown DJ, et al. (2000). Evaluation of biologically based dose-response modeling for developmental toxicity: a workshop report. Reg Appl Toxicol, 31, 190-9.
80. Lewis SC. (1993). Reducing uncertainty with adjustment factors. In: improvements in quantitative noncancer risk assessment. Fund Appl Toxicol, 20, 2-4.
81. Lewis SC, Lynch JR, Nikiforov AI. (1990). A new approach to deriving community exposure guidelines from no-observed-adverse-effect levels. Regul Toxicol Pharmacol, 11, 314-30.
82. Liao KH, Tan YM, Clewell III HJ. (2007). Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene. Risk Anal, 27, 1223-36.
83. Lipscomb JC, Haddad S, Poet T, Krishnan K. (2012). Physiologicallybased pharmacokinetic (PBPK) models in toxicity testing and risk assessment. Adv Exp Med Biol, 745, 76-95.
84. Lu FC. (1988). Acceptable daily intake: inception, evolution, and application. Regul Toxicol Pharmacol, 8, 45-60.
85. MAK Commission. (2012). List of MAK and BAT Values 2012.
86. Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area. Report No. 48. Deutsche Forschungsgemeinschaft. Wiley-VCH Verlag GmbH & Co. KGaA, pp. 158-9.
87. Martin MT, Judson RS, Reif DM, et al. (2009). Profiling chemicals based on chronic toxicity results from the U.S. EPA ToxRef Database. Environ Health Perspect, 117, 392-9.
88. Martin MT, Knudsen TB, Reif DM, et al. (2011). Predictive model of rat reproductive toxicity from ToxCast high throughput screening. Biol Reprod, 85, 327-39.
89. McClellan RO. (2011). Role of science and judgment in setting national ambient air quality standards: how low is low enough? Air Qual Atmos Health, 5, 243-58. DOI 10.1007/s11869-011-0147-2.
90. McLanahan ED, El-Masri HA, Sweeney LM, et al. (2012). Physiologically based pharmacokinetic model use in risk assessment- why being published is not enough. Toxicol Sci, 126, 5-15.
91. Meek ME. (2008). Recent developments in frameworks to consider human relevance of hypothesized modes of action for tumours in animals. Environ Mol Mutagen, 49, 110-16.
92. Meek ME, Bolger M, Bus JS, et al. (2013). A framework for "fit for purpose" dose response-assessment. Regul Toxicol Pharmacol, 66, 234-40.
93. Meek ME, Boobis AR, Crofton KM, et al. (2011). Risk assessment of combined exposure to multiple chemicals: a WHO/IPCS framework. Regul Toxicol Pharmacol, 60, S1-14.
94. Meek ME, Bucher JR, Cohen SM, et al. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol, 33, 591-653.
95. Meek ME, Klaunig JE. (2010). Proposed mode of action of benzeneinduced leukemia: interpreting available data and identifying critical data gaps for risk assessment. Chem Biol Interact, 184, 279-85.
96. Moolgavkar SH, Knudson Jr AG. (1981). Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst, 66, 1037-52.
97. Meek ME, Newhook R, Liteplo RG, Armstrong VC. (1994). Approach to assessment of risk to human health for priority substances under the Canadian Environmental Protection Act. Environ Carcin Eco R, C12, 105-34.
98. Naumann B, Meek ME, Dourson, ML, Ohanian, E. (2005). The future of chemical specific adjustment factors in risk assessment. Risk Policy Report, 12, 14. Available from: http://www.tera.org/Publications/risk%20policy%20report- nauman%20et%20al%202005.pdf [last accessed 10 March 2013].
99. NRC (National Research Council). (1983). Risk assessment on the federal government-managing the process. Washington, DC: National Academies of Science, National Academy Press.
100. NRC (National Research Council). (1989). Recommended daily allowances. Washington, DC: National Academy of Science, National Academy Press.
101. NRC (National Research Council). (1993). Issues in risk assessment. Washington, DC: National Academies of Science, National Academy Press.
102. NRC (National Research Council). (1994). Science and judgment in risk assessment. Washington, DC: National Academies of Science, National Academy Press.
103. NRC (National Research Council). (1996). Understanding risk. Washington, DC: National Academies of Science, National Academy Press.
104. NRC (National Research Council). (2004). Review of the army's technical guides on assessing and managing chemical hazards to deployed personnel. Washington, DC: National Academies of Science, National Academy Press.
105. NRC (National Research Council). (2006). Human Biomonitoring for Environmental Chemicals. Committee on Human Biomonitoring for Environmental Toxicants. Washington, DC: National Academies of Science, National Academy Press.
106. NRC (National Research Council). (2007a). Toxicity testing in the 21st century: a vision and a strategy. Washington, DC: National Academies of Science, National Academy Press.
107. NRC (National Research Council). (2007b). Applications of toxicogenomic technologies to predictive toxicology and risk assessment. Washington, DC: National Academy Press.
108. NRC (National Research Council). (2008a). Public participation in environmental assessment and decision making. Washington, DC: National Academies of Science, National Academy Press.
109. NRC (National Research Council). (2008b). Phthalates and cumulative risk assessment: the tasks ahead. Washington, DC: National Academies of Science, National Academy Press.
110. NRC (National Research Council). (2009). Science and decisions: advancing risk assessment. Washington, DC: National Academies of Science, National Academy Press.
111. OECD (Organisation for Economic Co-operation and Development). (2007). Guidance document on the validation of (quantitative) structure-activity relationship [(Q)SAR] models.
112. OECD Environment Health and Safety Publications Series on Testing and Assessment, No. 69. ENV/JM/MONO(2007)2.
113. Olin SS, Sonawane BR. (2003). Workshop to develop a framework for assessing risks to children from exposure to environmental agents. Environ Health Persp, 111, 1524-26.
114. Olipitz W, Wiktor-Brown D, Shuga J, et al. (2012). Integrated molecular analysis indicates undetectable change in DNA damage in mice after continuous irradiation at 400-fold natural background radiation. Environ Health Perspect, 120, 1130-36.
115. Pieters MN, Kramer HJ, Slob W. (1998). Evaluation of the uncertainty factor for subchronic-to-chronic extrapolation: statistical analysis of toxicity data. Regul Toxicol Pharmacol, 27, 108-18.
116. Pottenger LH, Gollapudi BB. (2010). Genotoxicity testing: moving beyond qualitative "screen and bin" approach towards characterization of dose-response and thresholds. Environ Mol Mutagen, 51, 792-9.
117. Pottenger LH, Schisler MR, Zhang F, et al. (2009). Dose-response and operational thresholds/NOAELs for in vitro mutagenic effects from DNA-reactive mutagens, MMS and MNU. Mutat Res, 678, 138-47.
118. President's Commission. (1997). Presidential/Congressional Commission on Risk Assessment and Risk Management. Available from: http://www.riskworld.com/ Nreports/1997/risk-rpt/pdf/EPAJAN.PDF [last accessed 10 March 2013].
119. Price PS, Han X. (2011). Maximum cumulative ratio (MCR) as a tool for assessing the value of performing a cumulative risk assessment. Int J Environ Res Public Health, 8, 2212-25.
120. Price PS, Schnelle KD, Cleveland CB, et al. (2011). Application of a source-to-outcome model for the assessment of health impacts from dietary exposures to insecticide residues. Regul Toxicol Pharmacol, 61, 23-31.
121. Renwick AG. (1991). Safety factors and establishment of acceptable daily intake. Food Addit Contam, 8, 135-50.
122. Renwick AG. (1993). Data derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit Contam, 10, 275-305.
123. Renwick AG. (1998a). Toxicokinetics in infants and children in relation to the ADI and TDI. Food Addit Contam, 15, 17-35.
124. Renwick AG, Lazarus NR. (1998b). Human variability and noncancer risk assessment-an analysis of the default uncertainty factor. Regul Toxicol Pharmacol, 27, 3-20.
125. Renwick AG, Dorne JL, Walton K. (2000). An analysis of the need for an additional uncertainty factor for infants and children. Regul Toxicol Pharmacol, 31, 286-96.
126. Renwick AG, Dorne JCM, Walton K. (2001). Pathway-related factors: the potential for human data to improve the scientific basis of risk assessment. HERA, 7, 165-80.
127. Renwick AG, Barlow SM, Hertz-Picciotto I, et al. (2003). Risk characterisation of chemicals in food and diet. Food Chem Toxicol, 41, 1211-71.
128. Rhomberg LR. (2011). Alliance for risk assessment (ARA) presentation. Available from: http://www.allianceforrisk.org/ARA-Dose-Response.htm [last accessed 10 March 2013].
129. Rhomberg LR, Goodman JE, Haber LT, et al. (2011). Linear low-dose extrapolation for noncancer health effects is the exception, not the rule. Crit Rev Toxicol, 41, 1-19.
130. Sand S, Portier CJ, Krewski D. (2011). A signal-to-noise crossover dose as the point of departure for health risk assessment. Environ Health Perspect, 119, 1766-74.
131. Schulte PA. (1989). A conceptual framework for the validation and use of biological markers. Environ Res, 48, 129-44.
132. SCOEL. (2010). Recommendation from the scientific committee on occupational exposure limits for propylene oxide. SCOEL/SUM/161. August 2010. Available from: http://ec.europa.eu/social/BlobServlet? docIdx00BC;6514&langIdx00BC;en [last accessed 10 Mar 2013].
133. Seed J, Carney EW, Corley RA, et al. (2005). Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol, 35, 664-72.
134. Shah I, Houck K, Judson RS, et al. (2011). Using nuclear receptor activity to stratify hepatocarcinogens. PLoS ONE, 6, e14584. doi:10.1371/journal.pone.0014584.
135. Shuey DL, Setzer RW, Lau C, et al. (1995). Biological modeling of 5-fluorouracil developmental toxicity. Toxicology, 102, 207-13.
136. Silverman KC, Naumann BD, Holder DJ, et al. (1999). Establishing dataderived adjustment factors from published pharmaceutical clinical trial data. HERA, 5, 1059-89.
137. Sipes NS, Martin MT, Reif DM, et al. (2011). Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data. Toxicol Sci, 124, 109-27.
138. Slikker Jr W, Andersen ME, Bogdanffy MS, et al. (2004a). Dosedependent transitions in mechanisms of toxicity. Toxicol Appl Pharm, 201, 203-25.
139. Slikker Jr W, Andersen ME, Bogdanffy MS, et al. (2004b). Dosedependent transitions in mechanisms of toxicity: case studies. Toxicol Appl Pharm, 201, 226-94.
140. Sonich-Mullin C, Fielder R, Wiltse J, et al. (2001). International programme on chemical safety. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul Toxicol Pharmacol, 34, 146-52.
141. Souza T, Kush R, Evans JP. (2007). Global clinical data exchange standards are here! Drug Discov Today, 12, 174-81.
142. Strawson J, Haber L, Dourson M, Barkhurst M. (2003). Approaches to determining "Unreasonable Risk to Health." Toxicology Excellence for Risk Assessment (TERA). December 29. Available from: http://nrwa.org/search/ mainresultland.aspx?cxx00BC;partner-pub-100834157457 3985%3A0126459385& cofx00BC;FORID%3A10&iex00BC;UTF-8&qx00BC;TERA [last accessed 10 March 2013].
143. Suter GW, Vermeire T, Munns Jr WR, Sekizawa J. (2003). Framework for the integration of health and ecological risk assessment. Hum Ecol Risk Assess, 9, 281-301.
144. Swartout JC, Price PS, Dourson ML, et al. (1998). A probabilistic framework for the reference dose (probabilistic RfD). Risk Anal, 18, 271-82.
145. Sweeney LM, Kirman CR, Albertini RJ, et al. (2009). Derivation of inhalation toxicity reference values for propylene oxide using mode of action analysis: example of a threshold carcinogen. Crit Rev Toxicol, 39, 462-86.
146. Swenberg JA, Richardson FC, Boucheron JA, et al. (1987). High- to lowdose extrapolation: critical determinants involved in the dose response of carcinogenic substances. Environ Health Persp, 76, 57-63.
147. Swenberg JA, Lu K, Moeller BC, et al. (2011). Endogenous versus exogenous DNA adducts: their role in carcinogenesis, epidemiology, and risk assessment. Toxicol Sci, 120, S130-45.
148. Teuschler LK, Dourson ML, Stiteler WM, et al. (1999). Health risk above the reference dose for multiple chemicals. Reg Toxicol Pharmacol, 30, S19-26. Available from: http://www.tera.org/Publications/Teuschler%20et%20al%201999.pdf [last accessed 10 March 2013].
149. Thomas RS, Black MB, Li L, et al. (2012a). A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol Sci, 128, 398-417.
150. Thomas RS, Clewell III HJ, Allen BC, et al. (2012b). Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: a five chemical case study. Mutat Res, 746, 135-43.
151. Truhaut R. (1991). The concept of acceptable daily intake: a historical review. Food Addit Contam, 8, 151-62.
152. USDA (U.S. Department of Agriculture). (2012). Microbial risk assessment guideline. Pathogenic microorganisms with focus on food and water. Interagency Microbiological Risk Assessment Guideline Workgroup July 2012. Publication Numbers: USDA/FSIS/2012-001 EPA/100/J12/00.
153. US EPA (U.S. Environmental Protection Agency). (1976). Interim Procedures and Guidelines for Health Risk and Economic Impact Assessments of Suspected Carcinogens. Available from: nepis.epa.- gov/Exe/ZyPURL.cgi? Dockeyx00BC;90160G00.txt [last accessed 24 Feb 2013].
154. US EPA (U.S. Environmental Protection Agency). (1986a). Guidelines for carcinogen risk assessment. Federal Register, 51, 33992-34003.
155. US EPA (U.S. Environmental Protection Agency). (1986b). Guidelines for the health risk assessment of chemical mixtures. Federal Register, 51, 34014-25.
156. US EPA (U.S. Environmental Protection Agency). (1989). Risk Assessment Guidance for Superfund. Volume I. Human Health Evaluation Manual (Part A). Washington, DC. EPA/540/1-89/002.
157. US EPA (U.S. Environmental Protection Agency). (1992). Risk Assessment Forum. Framework for Ecological Risk Assessment. Washington, DC. EPA/630/R-92/001.
158. US EPA (U.S. Environmental Protection Agency). (1994). Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry. Office of Health and Environmental Assessment. Washington, DC. EPA/600/8-90-066F.
159. US EPA (U.S. Environmental Protection Agency). (1996). Proposed guidelines for carcinogen risk assessment. Federal Register, 61, 17960-18011.
160. US EPA (U.S. Environmental Protection Agency). (1997). Office of Solid Waste and Emergency Response. Ecological Risk Assessment Guidance for Superfund: process for Designing and Conducting Ecological Risk Assessments - Interim Final. EPA 540-R-97-006. Available from: http://www.epa.gov/oswer/ riskassessment/superfund- problem.htm [last accessed 12 Sep 2011].
161. US EPA (U.S. Environmental Protection Agency). (1998). Risk Assessment Forum. Guidelines for Ecological Risk Assessment. Washington, DC. EPA/630/R-95/002F.
162. US EPA (U.S. Environmental Protection Agency). (1999). Office of Solid Waste and Emergency Response. Ecological Risk Assessment and Risk Management Principles for Superfund Sites, (Issuance of Final Guidance) (PDF) October 7, 1999. Available from: http://www.epa.gov/oswer/riskassessment/superfund-problem. htm [last accessed 12 Sep 2011].
163. US EPA (U.S. Environmental Protection Agency). (2000a). Handbook- Risk Characterization. Science Policy Council. Office of Science Policy. Office of Research and Development. EPA 100-B-00-002.
164. US EPA (U.S. Environmental Protection Agency). (2000b). Supplementary Guidance for Conducting Health Risk Assessment of Chemical Mixtures. EPA/630/R-00/002.
165. US EPA (U.S. Environmental Protection Agency). (2001). Office of Solid Waste and Emergency Response. Risk Assessment Guidance for Superfund, Volume I - Human Health Evaluation Manual. Part D: standardized Planning, Reporting and Review of Superfund Risk Assessments. Available from: http://www.epa.gov/oswer/ riskassessment/superfund-hhplanning.htm [last accessed 12 September 2011].
166. US EPA (U.S. Environmental Protection Agency). (2002a). A review of the Reference Dose (RfD) and Reference Concentration (RfC) processes. Risk Assessment Forum. EPA/630/P-02/002F.
167. US EPA (U.S. Environmental Protection Agency). (2002b, February 28). Determination of the appropriate FQPA safety factor(s) in tolerance assessment. Washington, DC: Office of Pesticide Programs.
168. US EPA (U.S. Environmental Protection Agency). (2003a). Framework for Cumulative Risk Assessment. Risk Assessment Forum. U.S. Environmental Protection Agency. Washington, DC. EPA/630/P-02/001F.
169. US EPA (U.S. Environmental Protection Agency). (2003b). Region 3. Multi-criteria Integrated Resource Assessment (MIRA). Available from: http://www.epa.gov/reg3esd1/data/mira.htm [last accessed 9 Feb 2012].
170. US EPA (U.S. Environmental Protection Agency). (2005). Guidelines for carcinogen risk assessment. U.S. Environmental Protection Agency. EPA/630/P-03/001b.
171. US EPA (U.S. Environmental Protection Agency). (2006a). A Framework for Assessing Health Risk of Environmental Exposures to Children (Final). National Center for Environmental Assessment. Office of Research and Development. Washington, DC, EPA/600/R- 05/093F.
172. US EPA (U.S. Environmental Protection Agency). (2006b). Office of Pesticide Programs. Registration Review Process. Available from: http://www.epa.gov/pesticides/oppsrrd1/registration-review/reg-review- process.htm [last accessed 10 Feb 2012].
173. US EPA (U.S. Environmental Protection Agency). (2006c). Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment (Final Report). National Center for
174. US EPA (U.S. Environmental Protection Agency). (2007). Framework for Metals Risk Assessment. Risk assessment Forum. Washington, DC. EPA 120/R-07/001.
175. US EPA (U.S. Environmental Protection Agency). (2009). Office of Air Quality Planning and Standards. Process for Reviewing National Ambient Air Quality Standards. Available from: http://www.epa.gov/ttn/naaqs/review2.html [last accessed 9 Feb 2012].
176. US EPA (U.S. Environmental Protection Agency). (2011a). U.S. Environmental Protection Agency & U.S. Department of Agriculture Tolerance Reassessment Advisory Committee of the National Advisory Council for Environmental Policy & Technology. Available from: http://www.epa.gov/ oppfead1/trac/[last accessed 12 Sep 2011].
177. US EPA (U.S. Environmental Protection Agency). (2011b). U.S. Environmental Protection Agency & U.S. Department of Agriculture Committee to Advise on Reassessment and Transition (CARAT) National Advisory Council for Environmental Policy & Technology. Available from: http://www.epa.gov/ oppfead1/carat/[last accessed 12 Sep 2011].
178. US EPA (U.S. Environmental Protection Agency). (2011c). Public Involvement in Registration Review. Available from: http://www.epa. gov/oppsrrd1/registration-review/public-involvement.htm [last accessed 12 Sep 2011].
179. US EPA (U.S. Environmental Protection Agency). (2011d). Office of Pesticide Programs. Ecological Risk Assessment: technical Overview. Available from: http://www.epa.gov/oppefed1/ecorisk-ders/[last accessed 12 Sep 2011].
180. US EPA (U.S. Environmental Protection Agency). (2011e). Guidance for applying quantitative data to develop data-derive extrapolation factors for interspecies and intraspecies extrapolation. External Review Draft, May. Risk Assessment Forum.EPA/100/J-11/001. Available from: http://www.epa.gov/raf/files/ ddef-external-review-draft05-11-11.pdf [last accessed 1 Aug 2012].
181. US EPA (U.S. Environmental Protection Agency). (2012a). Framework for Human Health Risk Assessment to Inform Decision Making. EPA External Review Draft. Office of the Science Advisor. Risk Assessment Forum. Washington, DC. 601-D12-001. Available from: http://www.epa.gov/raf/files/framework-document-7- 13-12.pdf [last accessed 1 Aug 2012].
182. US EPA (U.S. Environmental Protection Agency). (2012b). Office of Pesticide Programs. Pesticide Registration Review Status. Available from: http://www.epa.gov/oppsrrd1/registration-review/reg-review-status.htm [last accessed 9 Feb 2012].
183. US EPA (U.S. Environmental Protection Agency). (2012c). Environmental Protection Agency: notice of workshop and call for information on integrated science assessment for oxides of nitrogen. Federal Register, 77, 7149-7151.
184. US EPA (U.S. Environmental Protection Agency). (2012d). Office of Water. Integrated Planning Approach Framework (draft). Available from: http://www.epa.gov/npdes/pubs/integrated-planning-framework- draft.pdf [last accessed 9 Feb 2012].
185. US EPA (U.S. Environmental Protection Agency). (2012e). Vocabulary Catalog List Detail - Integrated Risk Information System (IRIS) Glossary. Available from: http://ofmpub.epa.gov/sor-internet/registry/termreg/ searchandretrieve/glossariesandkeywordlists/search.do? detailsx00BC;& glossaryNamex00BC;IRIS%20Glossary. [last accessed 1 Aug 2012].
186. US EPA (U.S. Environmental Protection Agency). (2012f). Integrated Risk Information System (IRIS) Chloroform. Available from: http://www.epa.gov/iris [last accessed 10 March 2013].
187. US EPA (US Environmental Protection Agency). (2012g). Advances in Inhalation Gas Dosimetry for Derivation of a Reference Concentration (RfC) and Use in Risk Assessment. EPA/600/R-12/044.
188. Vines TH, Andrew RL, Bock DG, et al. (2013). Mandated data archiving greatly improves access to research data. FASEB J, 27, 1304-8.
189. Waters MD, Fostel JM. (2004). Toxicogenomics and systems toxicology: aims and prospects. Nat Rev Genet, 5, 936-48.
190. WHO IPCS (World Health Organization. International Programme on Chemical Safety). (2006). Environmental Health Criteria 237- Principles for Evaluating Health Risks in Children Associated with Exposure to Chemicals. Geneva, Switzerland.
191. WHO IPCS (World Health Organization. International Programme on Chemical Safety). (2007). PART 1: IPCS Framework for Analysing The Relevance of a Cancer Mode of Action for Humans And Case- Studies. PART 2: IPCS Framework for Analysing the Relevance of a Non-Cancer Mode of Action for Humans. Geneva, Switzerland.
192. WHO IPCS (World Health Organization. International Programme on Chemical Safety). (2008). Uncertainty and data quality in exposure assessment. Part 1. Guidance document on characterizing and communicating uncertainty in exposure assessment. Harmonization Project Document No. 6. Geneva, Switzerland.
193. WHO IPCS (World Health Organization. International Programme on Chemical Safety). (2009a). Environmental Health Criteria 239 - Principles for Modeling Dose-Response for the Risk Assessment of Chemicals. Geneva, Switzerland.
194. WHO IPCS (World Health Organization. International Programme on Chemical Safety). (2009b). Environmental Health Criteria 240 - Principles and methods for the risk assessment of chemicals in food. Geneva, Switzerland.
195. WHO IPCS (World Health Organization. International Programme on Chemical Safety). (2010). Characterization and Application of Physiologically Based Pharmacokinetic Models in Risk Assessment. Harmonization Project Document No. 9. Geneva, Switzerland.
196. WHO (World Health Organization). (2011). Guidelines for Drinkingwater Quality. Fourth Edition. Geneva, Switzerland.
197. Whyatt RM, Rauh V, Barr DB, et al. (2004). Prenatal insecticide exposures and birth weight and length among an urban minority cohort. Environ Health Perspect, 112, 1125-32.
198. Woodruff TJ, Zota AR, Schwartz JM. (2011). Environmental Chemicals in Pregnant Women in the United States: NHANES 2003-2004. Environ Health Perspect, 119, 878-885. Available from: http://ehp03.niehs.nih.gov/article/info:doi/10. 1289/ehp.1002727 [last accessed 10 March 2013].
199. Yang Y, Abel SJ, Ciurlionis R, Waring JF. (2006). Development of a toxicogenomics in vitro assay for the efficient characterization of compounds. Pharmacogenomics, 7, 177-86.
200. Zhao Q, Gadagbui B, Dourson M. (2005). Lower birth weight as a critical effect of Chlorpyrifos: a comparison of human and animal data. Reg Toxicol Pharmacol, 42, 55-63.
201. Zhao Q, Unrine J, Dourson ML. (1999). Replacing the default values of 10 with data-derived values: a comparison of two different dataderived uncertainty factors for boron. Hum Ecol Risk Assess, 5, 973-83. Available from: http://www.tera.org/Publications/boron.pdf [last accessed 10 March 2013].
202. Zielhuis RL, van der Kreek FW. (1979). The use of a safety factor in setting health based permissible levels for occupational exposure. Int Arch Occup Environ Health, 42, 191-201.